Related references
Note: Only part of the references are listed.Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis
Shubing Jia et al.
ACTA DIABETOLOGICA (2021)
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial
Juergen Harreiter et al.
DIABETES OBESITY & METABOLISM (2021)
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial
Charlotte C. van Ruiten et al.
DIABETES OBESITY & METABOLISM (2021)
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study
Ele Ferrannini et al.
DIABETES OBESITY & METABOLISM (2020)
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
Amalia Gastaldelli et al.
DIABETES OBESITY & METABOLISM (2020)
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes
Ali Muhammed Ali et al.
DIABETES CARE (2020)
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes A Systematic Review and Network Meta-analysis
Apostolos Tsapas et al.
ANNALS OF INTERNAL MEDICINE (2020)
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Marco Castellana et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Serge A. Jabbour et al.
DIABETES CARE (2020)
Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study
Juana Carretero Gomez et al.
CANADIAN JOURNAL OF DIABETES (2019)
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
Athena Philis-Tsimikas et al.
DIABETES OBESITY & METABOLISM (2019)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Bernard Zinman et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials
Dimitrios Patoulias et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
Marco Castellana et al.
SCIENTIFIC REPORTS (2019)
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial
Juan P. Frias et al.
DIABETES OBESITY & METABOLISM (2018)
Obesity as a Disease
Jagriti Upadhyay et al.
MEDICAL CLINICS OF NORTH AMERICA (2018)
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Bernhard Ludvik et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
Maria J. Pereira et al.
DIABETES THERAPY (2018)
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
Maria J. Pereira et al.
DIABETES THERAPY (2018)
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Serge A. Jabbour et al.
DIABETES CARE (2018)
IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures
Luigi Angrisani et al.
OBESITY SURGERY (2018)
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
John Wilding et al.
DIABETES THERAPY (2018)
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults
Majid Ezzati et al.
LANCET (2017)
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants
Bin Zhou et al.
LANCET (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Measurement of Waist Circumference
Wen-Ya Ma et al.
DIABETES CARE (2013)
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Michael A. Nauck
AMERICAN JOURNAL OF MEDICINE (2011)
Bariatric surgery: an IDF statement for obese Type 2 diabetes
J. B. Dixon et al.
DIABETIC MEDICINE (2011)
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Lisa M. Neff et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2010)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Metabolic/Bariatric Surgery Worldwide 2008
Henry Buchwald et al.
OBESITY SURGERY (2009)
Obesity prevalence from a European perspective:: a systematic review
Anne Berghoefer et al.
BMC PUBLIC HEALTH (2008)
Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-Lite) in a community sample
RL Kolotkin et al.
QUALITY OF LIFE RESEARCH (2002)
The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction
C Verdich et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Share Paper
